Belgium's UCB to buy Ra Pharmaceuticals in $2.1 billion cash deal

UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, both companies reported on Thursday, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology.


Source: Reuters Health

Be the first to comment

Leave a Reply

Your email address will not be published.


*